Swedish Orphan Biovitrum appoints president and ceo
Geoffrey McDonough takes the role, joining the firm from Genzyme
McDonough has held several leading positions within Genzyme in the US since 2002, beginning his career with the firm in corporate development.
‘Geoff is well-recognised for his solid and broad commercial and clinical expertise and for his background in the orphan drug and niche speciality market,’ said Bo Jesper Hansen, chairman of Sobi.
‘He will lead Sobi toward our vision of becoming the leading niche speciality pharmaceutical company in Europe.’